Progress in treatment of lymphoma-associated hemophagocytic syndrome
10.3760/cma.j.cn115356-20211125-00274
- VernacularTitle:淋巴瘤相关噬血细胞综合征治疗研究进展
- Author:
Xingxing WANG
1
;
Junbin HU
Author Information
1. 华中科技大学同济医学院附属协和医院血液内科，武汉 430022
- Keywords:
Lymphohistiocytosis, hemophagocytic;
Hematologic neoplasms;
Treatment outcome;
Prognosis
- From:
Journal of Leukemia & Lymphoma
2022;31(9):571-573
- CountryChina
- Language:Chinese
-
Abstract:
Lymphoma-associated hemophagocytic syndrome (LAHS) accounts for a large proportion of secondary hemophagocytic syndrome (HPS) and has a poor prognosis. LAHS can be divided into two categories: HPS combined with chemotherapy and lymphoma-induced HPS. The key to the treatment of HPS combined with chemotherapy is to control the infection. While the treatment of lymphoma-induced HPS is complicated, there are new strategies in addition to traditional methods. Timely and appropriate treatment can significantly improve the short-term and long-term prognosis of patients. This article summarizes the progress in treatment of LAHS.
